PF-05280014: A Trastuzumab Biosimilar.
- Published in:
- BioDrugs, 2018, v. 32, n. 5, p. 515, doi. 10.1007/s40259-018-0308-z
- By:
- Publication type:
- Article
Works matching IS 11738804 AND DT 2018 AND VI 32 AND IP 5
Results: 14
1
2
SB5: An Adalimumab Biosimilar.
- Published in:
- BioDrugs, 2018, v. 32, n. 5, p. 507, doi. 10.1007/s40259-018-0307-0
- By:
- Publication type:
- Article
3
Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent.
- Published in:
- BioDrugs, 2018, v. 32, n. 5, p. 397, doi. 10.1007/s40259-018-0306-1
- By:
- Publication type:
- Article
4
ABP 980: A Trastuzumab Biosimilar.
- Published in:
- BioDrugs, 2018, v. 32, n. 5, p. 511, doi. 10.1007/s40259-018-0305-2
- By:
- Publication type:
- Article
5
Risk of Adverse Drug Events Observed with Baricitinib 2 mg Versus Baricitinib 4 mg Once Daily for the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Published in:
- BioDrugs, 2018, v. 32, n. 5, p. 415, doi. 10.1007/s40259-018-0304-3
- By:
- Publication type:
- Article
6
Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways.
- Published in:
- BioDrugs, 2018, v. 32, n. 5, p. 481, doi. 10.1007/s40259-018-0303-4
- By:
- Publication type:
- Article
7
Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody-Drug Conjugates.
- Published in:
- BioDrugs, 2018, v. 32, n. 5, p. 465, doi. 10.1007/s40259-018-0302-5
- By:
- Publication type:
- Article
8
Biosimilar Knowledge Among Oncology/Hematology Team Members in Colorado, USA: An Educational Initiative and Follow-Up Survey.
- Published in:
- BioDrugs, 2018, v. 32, n. 5, p. 499, doi. 10.1007/s40259-018-0301-6
- By:
- Publication type:
- Article
9
Ensuring Product Quality, Consistency and Patient Supply over Time for a Large-Volume Biologic: Experience with Remicade<sup>®</sup>.
- Published in:
- BioDrugs, 2018, v. 32, n. 5, p. 405, doi. 10.1007/s40259-018-0300-7
- By:
- Publication type:
- Article
10
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies.
- Published in:
- BioDrugs, 2018, v. 32, n. 5, p. 441, doi. 10.1007/s40259-018-0299-9
- By:
- Publication type:
- Article
11
Author’s Reply to Webster and Woollett: “The End of Phase 3 Clinical Trials in Biosimilars Development?”.
- Published in:
- BioDrugs, 2018, v. 32, n. 5, p. 523, doi. 10.1007/s40259-018-0298-x
- By:
- Publication type:
- Article
12
Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”.
- Published in:
- BioDrugs, 2018, v. 32, n. 5, p. 519, doi. 10.1007/s40259-018-0297-y
- By:
- Publication type:
- Article
13
Correction to: GP2015: An Etanercept Biosimilar.
- Published in:
- BioDrugs, 2018, v. 32, n. 5, p. 525, doi. 10.1007/s40259-018-0296-z
- By:
- Publication type:
- Article
14
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities.
- Published in:
- BioDrugs, 2018, v. 32, n. 5, p. 425, doi. 10.1007/s40259-018-0295-0
- By:
- Publication type:
- Article